Short answer
Lantheus Holdings, Inc. (LNTH) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $384M (up 1.4% year over year) with net income of $28M.
Q3 2025 key financials · XBRL
- Revenue
- $384M
- +1.4% YoY · +1.6% QoQ
- Net income
- $28M
- −78.8% YoY · −64.7% QoQ
- Operating margin
- 11.4%
- Gross margin
- 57.9%
- EPS (diluted)
- $0.46
- −74.6% YoY · −58.9% QoQ
Source: XBRL data from the Lantheus Holdings, Inc. (LNTH) Q3 2025 10-Q on SEC EDGAR. USD.
Lantheus Holdings, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added risk: Loss of transitional pass-through payment status (TPT Status) for PYLARIFY as of December 31, 2024, impacting reimbursement and competitiveness
- Most materially updated risk: CMS 2025 OPPS Rule unbundled diagnostic radiopharmaceutical payments, reducing PYLARIFY’s payment rate to below prior ASP-based amount, changing competitive dynamics
- Most impactful regulatory risk: Potential generic entry after PYLARIFY’s new chemical entity exclusivity expires May 26, 2026, threatening market share and pricing
- Operational risk: Transitioning customer invoicing from a PMF partner to Lantheus exposes risks of delayed invoicing, revenue loss, and reputational harm
- Financial risk: Approximately 20% of traditional Medicare FFS patients in hospital outpatient setting face lower reimbursement rates under new CMS rules, affecting revenue and cash flows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lantheus Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.